Indian regulator asks states to prevent online drug sales
The drugs regulator in India has asked all states to prohibit the sale of drugs online to prevent medicine abuse, according to a report.
List view / Grid view
The drugs regulator in India has asked all states to prohibit the sale of drugs online to prevent medicine abuse, according to a report.
The FDA has released a statement on the investigations into the presence of nitrosamines in some drugs; highlighting that there are currently no recalls of metformin within the US.
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
The US Food and Drug Administration has awarded APR-TD011 Orphan Drug Designation, for the treatment of a rare disease.
The amount of illegal diazepam tablets commandeered at the border of the UK doubled last year, according to a report.
The first three applications for generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of MS have been approved.
Dr Sodergren explores the uses of medical cannabis, describing its applications. He also discusses the future of cannabinoid research in the short- and long-term.
To further its investigation into the cause of the NDMA impurities found in ranitidine and nizatidine, the FDA has asked manufacturers of these products to expand their testing to include all lots of the medication.
A pharmaceutical company has announced its intention to create a pressurised Metered Dose Inhaler that will reduce the carbon footprint of the drug delivery system.
A study has revealed that in industrialising and urbanising countries, pharmaceutical pollution in rivers could lead to antimicrobial resistance.
A medicinal CBD oil has been approved for importation, prescription and supply under the Medical Cannabis Access Programme (MCAP) in Ireland.
The US Food and Drug Administration has announced new guidance for drug applications that include results from adaptive clinical trials.
The ABPI’s board has unanimously appointed Dr Richard Torbett as Chief Executive, commencing 1 January 2020.
In the wake of Brexit, the pharma industry will need to respond to a new regulatory landscape. Peter Morgan discusses how businesses have to prepare for the oncoming political changes, all whist retaining high pharmaceutical product quality.
A week-long awareness-raising campaign has been launched to combat the spread of substandard and falsified medicines.